Steve Shak Exact Sciences Chief Medical Officer discusses Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients
Steve Shak @ExactSciences Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Ca…
